Thomas P. Schnettler - Jul 8, 2025 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role: Director
Signature: /s/ Thomas P. Schnettler
Stock symbol: AKYA
Transactions as of: Jul 8, 2025
Transactions value $: $0
Form type: 4
Date filed: 7/10/2025, 08:38 PM
Previous filing: Apr 21, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
SCHNETTLER THOMAS P	Director	C/O AKOYA BIOSCIENCES, INC., 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH	/s/ Thomas P. Schnettler	2025-07-10	0001271857

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKYA	Stock Option (Right to Buy)	Other	$0	-16.9K	-100%	$0.00	Jul 8, 2025	Common Stock	16.9K	$21.95	Direct	F1, F2
transaction	AKYA	Stock Option (right to buy)	Other	$0	-30.5K	-100%	$0.00	Jul 8, 2025	Common Stock	30.5K	$11.24	Direct	F1, F2
transaction	AKYA	Stock Option (right to buy)	Other	$0	-56.3K	-100%	$0.00	Jul 8, 2025	Common Stock	56.3K	$5.70	Direct	F1, F2
transaction	AKYA	Stock Option (right to buy)	Other	$0	-50K	-100%	$0.00	Jul 8, 2025	Common Stock	50K	$2.01	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Thomas P. Schnettler is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.
F2	Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration (as defined in the Merger Agreement) was automatically terminated and cancelled for no consideration.

Content

Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.

Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration (as defined in the Merger Agreement) was automatically terminated and cancelled for no consideration.